The genus Mycobacterium is one of the most important bacterial genera. It includes several commensal microorganisms and pathogens, such as Mycobacterium tuberculosis and Mycobacterium leprae, the causative agents of two of the major infectious diseases affecting human populations worldwide. Until quite recently, mycobacteria have been relatively refractory to molecular biological approaches, because of the difficulty of introducing foreign DNA into these cells and the lack of suitable mycobacterial cloning vectors. However, since the development of efficient electroporation into mycobacteria (39) and the isolation of autonomously replicating plasmids derived from the Mycobacterium fortuitum plasmid pAL5000 (21) , this genus has become increasingly the focus of molecular investigations. In addition, the use of recombinant Mycobacterium bovis BCG has recently shown promise as a bacterial live vaccine carrier (11, 41, 42) .
Despite their importance as microbial pathogens and heterologous expression systems, little is known about the structures of mycobacterial gene promoters and their activities. Usually, mycobacterial promoters function very poorly in heterologous hosts such as Escherichia coli (10, 38) , and vice versa, relatively few heterologous promoters have been shown to be functional in mycobacteria, suggesting that the mycobacterial promoters are only distantly related to the promoters of other microorganisms. The most extensively studied and used promoter is that controlling the mycobacterial heat shock protein genes (42, 46) . Sequence comparison of this promoter region with other bacterial promoters revealed some similarities with consensus promoter sequences ( 70 and 32 promoters). However, mycobacterial promoters controlling the expression of heat shock proteins are among the rare ones that have been shown to be active in E. coli (46) and may therefore not necessarily be representative of mycobacterial promoter structures. More recently, other mycobacterial promoters isolated from Mycobacterium paratuberculosis and M. fortuitum were also found to contain well-conserved Ϫ10 and Ϫ35 regions (28, 47) . Again, these promoters were active in E. coli. Other promoters have been used but have not been extensively studied.
To gain insight into the structure and function of a specific mycobacterial promoter, we analyzed the promoter region controlling the expression of the M. tuberculosis 85A antigen in M. bovis BCG and Mycobacterium smegmatis. The 85A antigen is part of a secreted antigenic complex and represents one of the major secreted proteins from slowly growing mycobacteria (50) . The structural genes of these antigens have been cloned and sequenced from several mycobacterial species (5, 9, 12, 24, 34) . Whereas the coding regions of these genes share a high degree of sequence similarity, the noncoding sequences display more divergence. In this study, we used the E. coli phoA gene as a reporter gene and found that the M. tuberculosis 85A promoter was active in BCG and in M. smegmatis but inactive in E. coli. Progressive deletion experiments and primer extension analysis identified the region essential for efficient promoter activity. In addition, the 85A antigen promoter and its signal peptide were successfully used for the production and secretion of the heterologous antigen Sm28GST from Schistosoma mansoni in BCG.
MATERIALS AND METHODS
Bacterial strains and growth conditions. All cloning steps were performed in E. coli XL1-Blue (Stratagene, La Jolla, Calif.). E. coli CC118 (PhoA Ϫ ) was kindly provided by C. Manoil (23) . Expression studies were done in M. bovis BCG (vaccine strain 1173P2) and in M. smegmatis mc 2 155 (40) , an efficient plasmid transformation mutant of M. smegmatis mc 6 (generously provided by T. Kieser). Cultures of M. bovis BCG or M. smegmatis (150 ml) were grown to mid-log phase in Sauton medium (36) and were then centrifuged at 4,500 ϫ g for 15 min. The pellets were resuspended in 150 ml of 10% glycerol. Cells were centrifuged again, washed three times with 75 ml of 10% glycerol, and resuspended in 5 ml of 10% glycerol. Competent mycobacteria were then aliquoted and frozen at Ϫ80ЊC until further use. For transformation, the DNA sample was mixed with 50 l of cell suspension and pulsed with a Cellject electroporator (Eurogentec, Liège, Belgium) at 2,500 V, 412 ⍀, and 40 F. The cells were then recovered in 1 ml of Sauton medium and plated onto Middlebrook 7H10 medium supplemented with ADC enrichment (Difco, Detroit, Mich.) containing 0.01% cycloheximide and either 20 g of kanamycin or 15 g of streptomycin per ml. The plates were incubated at 37ЊC, and colonies were isolated after 3 to 4 days (M. smegmatis) or 15 to 20 days (BCG).
Plasmids and DNA manipulation. The pUC18 and pUC19 vectors and pBluescript SKϩ/Ϫ vector were purchased from New England Biolabs (Beverly, Mass.) and Stratagene, respectively. pHP45⍀ (31) and pUC4K (Pharmacia LKB, Uppsala, Sweden) were used to isolate the streptomycin and kanamycin resistance genes, respectively. pT7T3-19UphoA1-2-3 (19) containing the phoA-coding sequence was a gift from F. Rüker, pRR3 (33) derived from M. fortuitum pAL5000 (21) was kindly provided by B. Gicquel, and pT7-4 and pGP1-2 (44) came from S. Tabor. The clone BS-BY-5A was obtained by inserting a 800-bp HindIII fragment from the previously described BY-5 (5) into Blue Scribe M13ϩ (Stratagene). Restriction analysis of plasmids from mycobacteria was performed after electroduction in E. coli as described by Baulard et al. (3) .
Restriction enzymes, T4 DNA polymerase, polynucleotide kinase, Klenow fragment, BAL 31, and other DNA-modifying enzymes were purchased from Boehringer GmbH (Mannheim, Germany), Pharmacia LKB, New England Biolabs, or Eurogentec. Moloney murine leukemia virus reverse transcriptase was purchased from Gibco BRL (Gaithersburg, Md.). All DNA manipulations were performed under standard conditions as described by Sambrook et al. (35) .
Vector construction using the 85A promoter and signal peptide. To fuse the 85A promoter and signal peptide-coding sequence to the E. coli phoA reporter gene, a 544-bp fragment corresponding to the 85A promoter region followed by the sequence encoding the 85A signal peptide was amplified by PCR from plasmid BS-BY-5A, using the reverse primer (Boehringer) and a 32-mer primer (5ЈCGCGGATCCGCCCCCGCGGTCGCCGTGCCACC3Ј). This oligonucleotide, containing a BamHI site at its 5Ј end, was synthesized by Transgène (Strasbourg, France). The PCR product was then digested with HindIII-BamHI and cloned into HindIII-BamHI-digested pUC18 to generate a plasmid designated pEC001. In parallel, pHP45⍀ was digested by SmaI to isolate the streptomycin resistance gene (2.1 kb), which was subsequently ligated into an EcoRV-linearized pT7T3-19UphoA1-2-3 (pEL1). The purified 4.4-kb SmaI fragment of pEL1 containing the phoA coding sequence and the streptomycin resistance gene was cloned into pEC001 previously digested with BamHI and blunt ended with Klenow fragment. The resulting plasmid (pEL2) was digested with SacI and XbaI, and the 4-kb insert (containing the 85A promoter and signal peptidecoding sequence and the phoA and the streptomycin resistance genes) was isolated, filled in with Klenow fragment, and ligated into the unique ScaI site of pRR3, a mycobacterium-E. coli shuttle vector. M. smegmatis and BCG were transformed with this final construct (pEND1; Fig. 1 ) and were selected for streptomycin resistance.
To construct the vector for expression of the Sm28GST gene, the Sm28GST-coding sequence was amplified from clone TG10 (30a) by PCR, using synthetic oligonucleotides with the following sequences: 5ЈTAAGATCTCCATGGCTG GCGAGCAT3Ј and 5ЈTAAGATCTCCGAGCTTTCTGTTG3Ј (Fig. 2) . The 780-bp fragment was then digested with BglII, blunt ended with Klenow fragment, and cloned into SmaI-linearized pEC002, generating pEC008. To construct pEC002, a 545-bp fragment corresponding to the 85A promoter and secretion signal was amplified by PCR from plasmid BS-BY-5A by using the reverse primer and a 33-mer oligonucleotide (5ЈCGCGGATCCTGCCCCCGCG GTCGCCGTGCCACC3Ј). This oligonucleotide contains a BamHI site at its 5Ј end and was synthesized by Transgène. The PCR product was then digested with HindIII-BamHI and cloned into HindIII-BamHI-restricted pUC19. The 1,300-bp HindIII-EcoRI insert of pEC008 was then cloned into HindIII-EcoRI-digested pBluescript SKϩ/Ϫ, thereby yielding pEC009. The 1,300-bp SalI kanamycin resistance gene was then excised from pUC4K and introduced into the compatible XhoI restriction site of pEC009, thereby giving rise to pEC010. To construct pEN00X4, the 2,700-bp Asp 718 insert isolated from pEC010 was filled in with Klenow fragment at both ends and ligated into the PstI-digested pRR3⌬Kan shuttle vector previously treated with T4 DNA polymerase to remove the protruding ends. pRR3⌬Kan consists of pRR3 which was deleted of its kanamycin resistance gene by PstI restriction. pEN00X4 was then introduced into BCG, and recombinants were selected for kanamycin resistance.
To construct the phoA gene expression vector under the control of the T7 10 promoter (44), the DNA fragment containing the phoA gene fused to the 85A signal peptide-coding region and the streptomycin resistance gene was isolated from pEL2 after digestion with PstI and XbaI and cloned into pT7-4 digested with PstI and XbaI. The resulting plasmid, named pT7-418, was selected by its ability to confer resistance to streptomycin and was then transformed into E. coli CC118 containing pGP1-2. The recombinant E. coli cells were then grown for several hours at 30ЊC in LB supplemented with ampicillin (100 g/ml) and kanamycin (25 g/ml) until the optical density at 600 nm (OD 600 ) reached 0.4. Expression of the T7 RNA polymerase gene was achieved by raising the temperature to 42ЊC for 30 min. The temperature was then reduced to 37ЊC, and growth was continued for an additional 90 min under constant shaking before the cells were assayed for PhoA activity.
Preparation of RNA. Sodium azide (10 mM, final concentration) was added to a 150-ml M. bovis BCG culture grown to mid-log phase. The cells were then harvested by centrifugation (4,000 ϫ g for 20 min at 4ЊC), resuspended in TE (50 mM Tris-HCl [pH 8.0], 5 mM EDTA) containing 1.3 mg of lysozyme (Sigma, St. Louis, Mo.) per ml, and incubated for 1.5 h at 37ЊC under constant shaking. The bacterial cell walls were disrupted at 60ЊC for 2 h by adding 3% sodium dodecyl sulfate (SDS) and 500 g of proteinase K (Boehringer) per ml. After centrifugation at 8,000 ϫ g for 10 min at 4ЊC, the supernatant was recovered, and total cellular RNA was extracted with an equal volume of phenol-chloroform (1:1; pH 8.0), centrifuged at 8,000 ϫ g for 20 min at room temperature, and extracted again with 1 volume of phenol-chloroform (1:1; pH 4.5). Following centrifugation at 8,000 ϫ g for 10 min at room temperature, the aqueous phase was mixed with 1 volume of ether, centrifuged, and precipitated with 2.5 volumes of ethanol-0.3 M sodium acetate-0.1% SDS. The RNA was pelleted (8,000 ϫ g for 45 min at 4ЊC), washed with 75% ethanol, dried, redissolved in diethyl pyrocarbonate-treated water, and stored at Ϫ80ЊC until further use.
Nucleotide sequence determination. Nucleotide sequences were determined from double-stranded DNA by the dideoxyribonucleotide chain termination method, using [␣- Primer extension. Ten micrograms of total RNA was subjected to primer extension using a 30-mer oligonucleotide (5ЈTCCCATTCTTGCTTCCCTCATC CTCATCTC3Ј). The 5Ј hydroxyl end of the primer (500 ng) was radiolabeled for 45 The primer extension products as well as the sequencing reactions were denatured at 80ЊC for 5 min and separated by electrophoresis on a 6% polyacrylamide-8 M urea sequencing gel.
Immunoblotting of recombinant proteins. Ten-milliliter aliquots of cultures were harvested at mid-log phase. The cells were centrifuged and resuspended in 1.5 ml of phosphate-buffered saline (PBS; 20 mM K 2 HPO 4 [pH 7.5], 0.15 M NaCl) and disrupted for 10 min with a Branson Sonifier 450 at half-maximal constant output. The resulting BCG or M. smegmatis crude extracts were then separated on an SDS-12% polyacrylamide gel as described by Laemmli (22) . After electrophoresis, proteins were transferred onto a Hybond-C Extra membrane (Amersham France). The membrane was then saturated with 5% dry milk in PBS-0.1% Tween 20. Anti-Sm28GST 190-211 peptide rat polyclonal antibodies used to detect the Sm28GST antigen were kindly provided by G. Renauld and N. Mielcarek (Institut Pasteur de Lille, Lille, France). These antibodies were generated by intradermal injection of 50 g of 190-211 peptide with incomplete Freund adjuvant in Fischer rats. Animals were then boosted with 50 g of peptide 3 weeks later and reboosted 6 weeks later, and antisera were recovered 10 days after the second boost. Purified E. coli alkaline phosphatase (PhoA) and monoclonal antibody (code number ME6200) against the E. coli PhoA were purchased from Sigma and Caltag Laboratories (San Francisco, Calif.), respectively. Goat anti-rat alkaline phosphatase-conjugated antibodies and goat antimouse alkaline phosphatase-conjugated antibodies were purchased from Immunotech (Marseille, France) and Promega (Madison, Wis.), respectively.
Alkaline phosphatase assay. Mycobacteria were harvested by centrifugation and washed in PBS. The final cell pellet was resuspended in 1 ml of 1 M Tris-HCl (pH 8.0). Nine hundred microliters of 1 M Tris-HCl (pH 8.0) and 100 l of 20 mM p-nitrophenylphosphate (Sigma) were added to 100 l of the cell pellet or culture supernatant. Enzymatic reactions were performed in triplicate in the dark at 37ЊC. Reactions were stopped with 100 l of 1 M K 2 HPO 4 , and the OD 420 was measured. The PhoA activities were measured as described by Manoil and Beckwith (23) . The recombinant mycobacteria were also analyzed by immunoblotting with anti-Aph antibodies, kindly provided by E. Collatz, to ensure that they all contained similar amounts of Aph and that therefore the pEND series of plasmids had similar copy numbers in the different strains.
BCG infection in mice. Eight-week-old C3H/HeJ (H-2 k ), C57BL/6 (H-2 b ), and BALB/c (H-2 d ) female mice (Iffa Credo, l'Arbresle, France) were used for BCG infection. Mice were inoculated subcutaneously or intravenously with 10 7 BCG which had been grown for 2 weeks in Sauton medium and measured by OD 600 . They were immunized either with untransformed BCG or with recombinant BCG expressing Sm28GST antigen.
Antigen preparation. Sm28GST antigen was purified by affinity chromatography on a glutathione-agarose column as described previously (49) . provided by André Tartar (Institut Pasteur de Lille), were synthesized by solidphase synthesis according to the Merrifield method (27) . Soluble worm adult proteins (SWAP) were prepared from adult worms washed in PBS, passed rapidly from Ϫ196 to 37ЊC, disrupted by sonication for 30 s, and then centrifuged at 10,000 ϫ g for 20 min. The supernatant was collected and frozen. Soluble egg antigen (SEA) was prepared by the method of Boros and Warren (4). SWAP and SEA are crude extracts of S. mansoni containing Sm28GST antigen.
Lymphoproliferation assay. Three weeks after immunization, spleen and lymph node cells were isolated and resuspended in RPMI 1640 (Gibco, Courbevoie, France) containing 20 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid) and 10% heat-inactivated fetal calf serum (Boehringer) and supplemented with 2 mM L-glutamine, 5 ϫ 10 Ϫ5 M ␤-mercaptoethanol (Merck, Darmstadt, Germany), and 1 mM sodium pyruvate (Gibco). Cells were cultured at a concentration of 2.5 ϫ 10 5 cells per well in 96-well flat-bottom culture plates in the presence of Sm28GST antigen (20 g/ml), Sm28GST-derived peptides (20 g/ml), SWAP (20 g/ml), SEA (20 g/ml), or purified protein derivative (0.5 U per well; Diagnostics Pasteur, Marnes-la-Coquette, France). As positive T-cell proliferation controls, concanavalin A and staphyloccocal enterotoxin B were added at concentrations of 5 and 1 g/ml, respectively. The assays were performed in triplicate. Cultures were incubated at 37ЊC in a humidified CO 2 incubator for 4 days and then pulse-labeled with 18.5 kBq of [ 3 H]thymidine (25 Ci/mmol; Amersham France) in order to measure T-cell proliferation. The cells were harvested 12 to 16 h later onto fiber filter strips, using a multiharvester (Skatron, Lierbyen, Norway), and the radioactivity incorporated into DNA was determined by liquid scintillation counting (LKB, Turku, Finland). Results are expressed as mean counts per minute minus the background (medium alone). Significant proliferation was defined by the Student t test.
RESULTS
Expression and secretion of alkaline phosphatase in BCG and M. smegmatis. The M. tuberculosis 85A antigen, one of the major secreted and cell surface-associated proteins, has been proposed to be involved in mycobacterial adherence (1) . Therefore, this antigen could be an important virulence factor, and the study of its expression signals should shed some light on mycobacterial promoter structures and possibly gene regulation. We used the M. tuberculosis 85A promoter and export signal to study the expression and secretion of heterologous proteins in mycobacteria. For this purpose, we constructed a shuttle vector in which the alkaline phosphatase gene (phoA) of E. coli was cloned downstream of the 85A promoter and secretion signal (Fig. 1) .
PhoA of E. coli hydrolyzes organic phosphate esters as an active homodimer only when it is secreted at least through cytoplasmic membrane (48) . We expected that the phoA gene product would be exported through the mycobacterial membrane because of its fusion to the 85A signal peptide. Accordingly, expression and secretion studies were performed by measuring PhoA activity directly on intact recombinant cells and in the culture supernatants. After 4 h of reaction, a yellow color was readily detected in the mycobacterial cell suspensions and in the culture supernatants of recombinant BCG and M. smegmatis, indicating that the 85A signals can drive phoA expression and PhoA secretion in both mycobacterial species.
The PhoA activities were significantly higher in recombinant BCG than in untransformed cells used as controls (Fig. 3) . Recombinant BCG expressed typically 35 U of PhoA activity, whereas nonrecombinant BCG expressed approximately 10-fold less activity. Similar results were obtained for M. smegmatis (data not shown). The same levels of PhoA activity were obtained when the mycobacteria carrying pEND1 were disrupted by sonication prior to the measurement of PhoA activity (data not shown). This result suggests that the PhoA produced in these mycobacteria is exported through the mycobacterial membrane. PhoA was also detected by immunoblotting using a monoclonal antibody specific for E. coli PhoA (Fig. 4) . A single immunoreactive band comigrating exactly with the purified E. coli PhoA was detected. The uncleaved signal peptide would have added at least 30 amino acids, thereby increasing the molecular mass by approximately 2.7 kDa. This difference would have been detected by the immunoblot performed under the conditions described for Fig. 4 . We therefore conclude that the signal peptide was completely removed in the mycobacterial cells, which confirms that most of the PhoA had crossed the cell membrane. Whereas PhoA was readily detectable in crude extracts of recombinant cells, its concentration in unconcentrated culture supernatants was too low to be detected by immunoblotting, although enzyme activity could be detected in the culture supernatants. These results show that both mycobacterial species constitute permissible hosts for E. coli phoA gene expression and PhoA secretion but that the release of PhoA into the culture supernatant is rather inefficient.
To determine whether PhoA might be useful for blue/white screening in mycobacteria (for example, to isolate new strong promoters in BCG or to isolate mutants deficient in the production of exported proteins by phoA-containing transposons), we cultured untransformed and recombinant BCG on Middlebrook 7H10 medium containing the PhoA substrate 5-bromo-4-chloro-3-indolyl phosphate (BCIP). However, the difference in colony staining in pEND1-containing mycobacteria versus untransformed mycobacteria was not significant. It thus appeared that the background activity caused by an endogenous mycobacterial alkaline phosphatase is too strong to permit the use of this system for rapid screening on indicator plates. Deletion analysis of the 85A promoter region. The phoA expression system was then used to study the structure of the M. tuberculosis 85A promoter. For this purpose, pEND1 was linearized at its unique KpnI site located a few nucleotides upstream of the 85A promoter region (Fig. 1) . BAL 31 nuclease was then used for progressive deletions of its 5Ј end. The plasmids digested by BAL 31 were directly ligated, transformed into E. coli XL1-Blue, and analyzed by restriction enzyme digestion. A single kanamycin-sensitive and nine different kanamycin-resistant pEND1 derivatives of different sizes were then used to transform BCG and M. smegmatis. The PhoA activities of the recombinant mycobacteria were then measured on intact cells. Figure 3 shows the PhoA activities of recombinant BCG as a function of the length of the deleted regions. Two sets of mutants were defined according to the levels of PhoA activity in the different mycobacteria. With the first set of plasmids (pEND22, pEND32, pEND41, and pEND61), significant PhoA activity was detected on the cell surface. However, these mutants consistently exhibited somewhat lower PhoA activity than the original pEND1-containing mycobacteria, suggesting that the sequences which were deleted by BAL 31 in these clones may play a role in the level of expression. Alternatively, it is possible that some vector sequence upstream of the KpnI site, especially the aph gene and its adjacent sequences deleted by the BAL 31 digestion, might have some effect on the 85A promoter activity in the pEND series of plasmids. However, when the aph gene was placed downstream rather than upstream of the 85A-phoA fusion gene (20a), the PhoA activity measured on the recombinant mycobacteria was very similar to that measured for pEND1-transformed mycobacteria. This result suggests that the aph gene sequences have no dramatic effect on the 85A promoter activity in pEND1.
A second group of mutants (pEND71, pEND122, pEND 113, pEND112, and pEND141) did not give any significant enzymatic activity (same level as for untransformed cells). These latter results were confirmed by immunoblotting (Fig.  4) . For example, while PhoA was clearly present in pEND61-containing cells, no specific immunoreactive band could be detected in pEND71-containing cells. This observation together with the enzyme assay data indicated that BAL 31 had removed indispensable parts of the 85A promoter in pEND71. However, the deletion in pEND71 also removed two ATG triplets that are in the same reading frame as the 85A signal peptide. Since the actual ATG start codon has not been defined yet, it could be possible that in addition to indispensable promoter sequences, the translational initiation sequence was also removed in the pEND71 construct. pEND1, pEND22, pEND41, pEND61, pEND71, and pEND 113 were also introduced into E. coli CC118 (PhoA Ϫ ) and grown on LB agar containing BCIP. In contrast to the E. coli CC118 cells that were transformed with pT7T3-19UphoA used as a positive control, all colonies were white, indicating that these phoA constructs were not expressed in E. coli. In addition, no 85A-PhoA mRNA was detected under conditions in which the 85A mRNA could readily be detected in BCG (data not shown). To exclude the possibility that the absence of PhoA activity in E. coli transformed with the pEND1 series of plasmids was due to the improper translation of the mRNA, improper transport of the protein, or improper cleavage of the signal peptide, rather than to the deficiency of the promoter activity, the phoA gene fused to the 85A signal peptide-coding region was cloned downstream of the T7 10 promoter. In the presence of the T7 RNA polymerase-coding gene, this construct was found to induce the production of active PhoA in permeabilized E. coli CC118 (data not shown). This result demonstrates that the 85A-PhoA mRNA can be translated in E. coli and that the protein can be translocated through the inner membrane by the 85A antigen signal peptide. This result confirms that neither the complete sequence of the 85A promoter (pEND1) nor a truncated form (pEND22, pEND41, pEND61, pEND71, or pEND113) is used by the E. coli transcription machinery.
The deletions in pEND22, pEND61, and pEND71 were further defined by DNA sequencing. In pEND22, 44 bp were removed by the BAL 31 nuclease. In pEND61, 266 bp were lost, while in pEND71, an additional 111-bp fragment was removed (Fig. 5) . These results show that a region essential for promoter activity in mycobacteria is located between nucleotides 275 and 385 of the sequence shown in Fig. 6 . During the sequence analysis, we noticed the following differences from the previously published sequence (9) in this promoter region: an insertion of GC at position 107, TA instead of AT at positions 171 and 172, and an insertion of a G at position 176. The numbers refer to the nucleotide positions of the sequence shown in Fig. 6 . The sequence shown in this figure was independently confirmed by sequencing PCR products from plasmid BS-BY-5A. In addition, chromosomal BCG DNA amplified by PCR also had a sequence identical to that shown in Fig.  6 .
Identification of the transcriptional start site. The transcriptional start site of the 85A-phoA fusion gene within pEND1 was determined by primer extension analysis (Fig. 7) . The results revealed a unique transcriptional start site located 63 bp upstream of the ATG initiation codon of the signal peptide sequence proposed previously (5) (Fig. 6 ). Of course, we can- not entirely exclude the possibility that the transcriptional start site determined by primer extension corresponds in fact to a premature stop site of the reverse transcriptase reaction. However, it is more likely that the primer extension experiment identified a bona fide transcriptional start site, because computer analysis of this region of the mRNA did not reveal any significant features, such as putative hairpin structures, known to prematurely arrest reverse transcription. Furthermore, the sequencing reactions in this region showed no signs of band compression. In addition, the primer extension results are consistent with the phoA expression results and further define the promoter structure of the 85A antigen gene between nucleotides 275 and 347. The nucleotide sequences centered around the Ϫ10 and Ϫ35 positions from the transcriptional start site were compared with sequences of other promoter structures and are shown in Fig. 8 . No obvious sequence similarities were found between the Ϫ10 region of the 85A antigen gene and other mycobacterial Ϫ10 regions or the Ϫ10 consensus sequences of 70 promoters. In contrast, a region centered around position Ϫ35 showed some sequence similarities (3 of 6 bp) with the consensus Ϫ35 region of 70 promoters. An even better alignment (5 of 6 bp) was obtained with a sequence positioned 22 bp upstream of the Ϫ10 hexamer. The ϩ1 nucleotide as well as the Ϫ10 and Ϫ35 boxes are present in pEND61 but are absent in pEND71, consistent with the fact that BCG (pEND61) expresses the phoA gene and BCG (pEND71) does not.
Effect of the distance separating the ؊35 and ؊10 regions on phoA expression. As shown in Fig. 8 , two putative Ϫ35 regions were identified in the 85A antigen promoter region. One is located at the (for E. coli) optimal 17-bp distance of the Ϫ10 region but with only 50% identity to the consensus Ϫ35 sequence, and one shows 83% identity to the consensus sequence but is located at a (for E. coli) suboptimal 22-bp distance to the Ϫ10 region. Since it is not known whether the presence of the Ϫ10 and Ϫ35 regions and/or their distance is of importance for promoter activity in mycobacteria, we decided to alter the distance between the Ϫ10 region and the two putative Ϫ35 regions and to analyze these alterations for their effects on promoter activity. To shorten the distance by 4 bp, pEND1 was linearized at its unique ApaI site (located between the two regions; Fig. 6 ), cut back with T4 DNA polymerase to remove the 3Ј protruding ends, and religated with T4 DNA ligase. Several recombinant clones were analyzed for the absence of the ApaI site. The 4-bp shortening was then confirmed by DNA sequencing. One correct plasmid was selected and named pENA1. After introduction of pENA1 into BCG and selection of the recombinant clones for kanamycin resistance, the recombinant mycobacteria were analyzed for PhoA activity. Figure 9 shows that the PhoA activity of BCG(pENA1) was lower than that of the BCG(pEND1) control strain but still significantly higher than that of BCG transformed with negative control plasmids. These results suggest either that the distance between the Ϫ10 and Ϫ35 regions is not critical or that in the mutant, the more distal Ϫ35 region (showing 83% similarity to the consensus sequence) had replaced the originally functional more proximal Ϫ35 region (with 50% similarity to the consensus sequence). To distinguish between the two possibilities, an additional mutant was analyzed.
During the screening for the 4-bp deletion mutant at the ApaI site, we unexpectedly isolated another clone, named pENA2, that contained an insertion of 64 bp within the ApaI site. Sequence analysis of pENA2 revealed that this insertion corresponds to a fragment of the phoA gene. This unexpected insertion within the promoter region separates the Ϫ35 and Ϫ10 regions by more than 80 bp. As illustrated in Fig. 9 , the PhoA activity of this mutant after transformation into BCG was very similar to that of BCG(pENA1), indicating that increasing the distance between the Ϫ35 and Ϫ10 regions by 64 bp does not dramatically affect the expression level of the promoter. Sequence analysis of this insertion did not reveal the addition of an obvious new Ϫ35 region. Analysis of PhoA (5) is underlined, and the deduced amino acid sequence of the signal peptide is indicated. The transcriptional start site is shown by ϩ1, and the Ϫ35 and Ϫ10 regions are boxed. The dot shows the position up to which the BCG 85A antigen gene was sequenced (12, 20a) . Positions of the deletions in the pEND1 derivatives are indicated by the arrows for pEND22, pEND61, and pEND71. The unique ApaI restriction site is also shown.
FIG. 7.
Primer extension analysis. The radiolabeled oligonucleotide was hybridized to total RNA extracted from BCG(pEND1), and primer extension was performed with Moloney murine leukemia virus reverse transcriptase as described in Materials and Methods. The same oligonucleotide was also used as a primer for DNA sequencing. The sequence of the coding strand is shown. The underlined letter indicates the transcriptional start site.
activity in M. smegmatis(pENA1) and M. smegmatis(pENA2)
showed results similar to those obtained in BCG. As for the wild-type promoter region, E. coli CC118 containing either plasmid had no detectable PhoA activity, indicating that the mutant promoters remained inactive in E. coli.
To investigate whether either Ϫ35 region played any role for promoter activity, we digested pEND1 with KpnI and ApaI (see the restriction sites in Fig. 5) , blunt ended the digested plasmid, and religated it, thereby deleting the entire region containing both putative Ϫ35 boxes. After transformation of this plasmid into M. smegmatis, we were unable to detect any significant PhoA activity, indicating that the presence of the Ϫ35 region is absolutely required for promoter activity, although its position may not be critical.
Expression-secretion of the S. mansoni Sm28GST antigen in BCG, using the 85A promoter and signal peptide. To test whether the M. tuberculosis 85A promoter and signal peptide sequences might be useful for the production and secretion of heterologous antigens in a recombinant BCG vaccine strain, we spliced the coding sequence of the glutathione S-transferase of S. mansoni (Sm28GST) with the promoter and signal peptide-coding sequence of the 85A antigen. Sm28GST is a major protective antigen of S. mansoni, inducing between 40 and 80% of protection against schistosomiasis in rodents and primates, which makes it a promising vaccine candidate (6). The Sm28GST-coding sequence was amplified from clone TG10 by PCR and used to generate pEN00X4 (Fig. 2) .
After transformation of BCG with pEN00X4, the presence of Sm28GST in BCG cells and culture supernatant was analyzed by immunoblotting (Fig. 10) , using a rat antiserum raised against a synthetic peptide that corresponds to the Sm28GST portion comprised between amino acid residues 190 and 211. A protein reactive with this antiserum and of the expected size was detected both in crude extracts of BCG carrying pEN00X4 and in the corresponding culture medium. No anti-Sm28GST-reactive protein of this size was detected in untransformed BCG. This result indicated that Sm28GST is expressed and exported through the mycobacterial cell wall via the 85A promoter and signal sequences.
Immune response against Sm28GST induced by recombinant BCG. To investigate whether BCG containing pEN00X4 could generate a specific immune response against Sm28GST, three distinct mouse haplotypes, BALB/c (H-2 A significant antigen-specific proliferative response was observed when lymph node cells from BALB/c mice were restimulated by using Sm28GST, the 65-86 peptide, and SEA as recall antigens (Fig. 11) . A very low response was also observed in C57BL/6 mice. No specific stimulation was observed when the mice were immunized with nonrecombinant BCG or when cells were derived from the spleen, irrespective of the mouse strain, the route of inoculation (subcutaneous or intravenous), or the BCG strain used (data not shown).
DISCUSSION
The antigen 85 complex is composed of at least three different, closely related proteins named 85A, 85B, and 85C and is a major secretion product of several mycobacterial species. However, these proteins are also found associated with the bacterial cell surface (for a recent review, see reference 50). Their properties, especially the capacity to bind fibronectin (1), in addition to the surface association, make them attractive virulence factor candidates. The production of bacterial virulence factors is usually tightly and coordinately regulated at the transcriptional level in response to environmental signals (26) .
Little is known about mycobacterial virulence factors or about gene expression, gene regulation, and the influence of environmental conditions on expression levels. Identification of sequences involved in gene regulation and characterization of transcriptional signals should be useful for the understanding of mycobacterial pathogenesis and may also help to identify new antigens for the development of new vaccines against diseases such as tuberculosis and leprosy.
As a first step toward the understanding of gene expression and regulation, we have analyzed the promoter region of the 85A antigen of M. tuberculosis. The genes encoding the antigen 85 complex proteins of several species have been cloned and sequenced and show a high degree of sequence similarity in the coding regions (5, 9, 12, 24, 34) . In this report, we describe the construction of a mycobacterial shuttle vector (pEND1) in which the expression of the E. coli phoA reporter gene was placed under the control of the M. tuberculosis 85A promoter and signal peptide-coding sequences. Recombinant BCG or M. smegmatis carrying pEND1 produced active PhoA, indicating that the 85A promoter and signal sequence were able to efficiently drive PhoA through the mycobacterial cell membrane. Western blot (immunoblot) analysis confirmed that the signal peptide was removed after secretion. PhoA activity was also detected in the culture supernatants, suggesting that the enzyme is also secreted into the growth medium. However, release into the culture supernatant was not very efficient, since PhoA could not be detected by immunoblot analysis of unconcentrated culture supernatants. The system thus appears particularly useful for the evaluation of the functional levels of mycobacterial promoters and the characterization of mycobacterial signal peptides. While this report was in preparation, Timm et al. (47) also reported on the use of phoA to study a promoter region of an M. fortuitum ␤-lactamase gene in M. smegmatis. The PhoA expression-secretion system may also be of use for comparison of the expression levels of different promoters in BCG and M. smegmatis.
To characterize the 85A promoter, several deletion mutants of the 5Ј untranslated region were developed by BAL 31 digestion. Removal of the first 44 bp resulted in a decrease of PhoA activity of about 40%. Deletion of a further 222 bp had no dramatic effect on the expression level, whereas after an additional 111-bp deletion, no significant activity was detected by either enzymatic assays or immunoblotting. This result in-dicates that essential regions for the promoter activity are located between positions Ϫ26 and Ϫ136 from the 85A initiation codon previously proposed (5) . The transcriptional start site was found at position Ϫ63 from the initiation codon, implying that the promoter region is located between Ϫ63 and Ϫ136.
The specific recognition of prokaryotic promoter sites by RNA polymerase is largely mediated by associated sigma factors. In many bacterial species, most promoter sequences are recognized by 70 -like factors at two hexameric sequences centered around positions Ϫ10 and Ϫ35 from the transcriptional start site that are optimally separated by 17 Ϯ 1 bp in E. coli. Alignment of the region centered around position Ϫ10 from the transcriptional start site of the 85A antigen gene showed no significant sequence similarities to E. coli consensus promoters or to other mycobacterial promoter regions identified by S1 mapping or primer extension analysis, except for 50% identity found with the BCG mpb70 gene promoter and 50% identity found with the region centered around position Ϫ10 from the major transcriptional start site of the M. smegmatis ask gene (7) . This latter sequence is also rich in C and G, similar to the 85A Ϫ10 region, a feature also shared with the Ϫ10 region of the M. tuberculosis cpn60 gene (20) . Interestingly, the Ϫ10 hexamer of the 85A promoter shows some similarities to several streptomycete promoters, such as the kgmB-p, strpB-p, aacC9-p, afsA-p, and vph-p2 promoters (Fig. 8) . Moreover, like the 85A promoter, these streptomycete promoters are not typically expressed in E. coli (43) . Between positions Ϫ136 and Ϫ63 from the proposed translational start site in Fig. 6 , there is no other hexamer with more than 50% identity to the E. coli Ϫ10 consensus sequence.
Two putative Ϫ35 regions were found, one positioned at 17 bp from the Ϫ10 region, showing 50% identity with the E. coli consensus promoter, and one positioned at 22 bp from the Ϫ10 region, showing 83% identity with the E. coli consensus sequence and being identical to the Ϫ35 region of the M. leprae and M. tuberculosis 16S rRNA promoter region.
The unconventional Ϫ10 region and/or the 22-bp spacer between the Ϫ10 and the Ϫ35 regions could explain the lack of expression in E. coli. This is different from what has been found for two other, recently studied mycobacterial promoters, in which cases both the Ϫ10 and Ϫ35 regions were more similar to the E. coli consensus sequences (28, 47) and were found to be functional in E. coli. However, since most mycobacterial promoters do not function in E. coli, the 85A promoter may be more typical for mycobacteria. Since spacer mutations result in dramatic effects on promoter activities in other bacterial species, the position of each of the putative Ϫ35 regions was further investigated by a 4-bp deletion and a 64-bp insertion in the 85A promoter region. Neither mutation abolished gene expression, indicating that the position is not critical for promoter activity. This is similar to what has been found for Streptomyces promoters (15) . Also, Streptomyces promoter regions are usually CϩG rich, with an average CϩG content of about 60%, compared with 70% for coding regions (43) . The 85A antigen promoter region contains 27 CϩG within the 40 nucleotides upstream of the transcriptional start site. In that respect, it is interesting to note that mycobacterial genes are usually better expressed in streptomycetes than in E. coli (18) . That the presence of the region containing the Ϫ35 boxes is critical for promoter activity was indicated by the total loss of expression when the KpnI-ApaI DNA fragment was deleted. The requirement of individual bases for promoter activity within the identified region awaits analyses by site-directed mutagenesis.
No sequence similarities were found between the M. tuberculosis 85A antigen promoter region and the promoter regions (12, 20a) . This finding suggests that the different genes encoding the antigen 85 proteins are transcribed by different mechanisms, perhaps requiring different regulators. This possibility is consistent with the fact that the different genes coding for the 85 complex are not clustered within the mycobacterial genome (9, 34) and is also consistent with previous reports suggesting differential expression of the components of the mycobacterial antigen 85 complex (29, 30) . It would be of interest to compare the promoter activities of the 85A antigen gene with those of the 85B and 85C antigen genes, as well as with that of the MPT51 protein gene, which displays significant sequence similarities with the 85 complex proteins and was found adjacent to the 85A antigen gene in M. leprae (34) . The availability of the E. coli phoA gene as a functional reporter gene for mycobacteria renders this approach feasible. Recently, mycobacteria, especially BCG, have received considerable attention as hosts for the production of heterologous antigens. BCG is one of the first live bacterial vaccines used to immunize human populations and was found to present a very low incidence of serious side effects (51) . In addition, its adjuvant activities makes it an attractive vector for the development of recombinant vaccines (42) . For this purpose, several mycobacterial promoters have already been used to drive expression of cloned genes in BCG. Mycobacterial heat shock promoters (hsp60 and hsp70) allowed the production of a variety of different antigens, including human immunodeficiency virus type 1 antigens (2, 42), the Plasmodium falciparum CS protein (13) , the Borrelia burgdorferi OspA lipoprotein (41), gp63 of Leishmania major (8) . Recombinant BCG strains producing these antigens were found to induce specific immune responses to the heterologous proteins in animals. The 85B antigen promoter of Mycobacterium kansasii (also called ␣-K) has also been used to express a human immunodeficiency virus type 1 Gag P17 epitope as a fusion protein (25) . This system also allowed the induction of a specific T-cell response in mice (17) . We wanted to know whether the M. tuberculosis 85A antigen promoter and secretion signal could also be used to produce and secrete foreign antigens in BCG. Expression and secretion of the S. mansoni Sm28GST antigen was obtained, and mice immunized by a single dose of the recombinant BCG showed that lymph node T cells from BALB/c mice proliferated weakly but significantly in response to the recombinant Sm28GST, the 65-86 peptide, and SEA. No restimulation was observed in the C3H/HeJ mouse strain, and a very weak response was detected in the C57BL/6 strain.
The immune response obtained in this study is significantly weaker than that described by other laboratories using the hsp promoters or the more recently identified P AN promoter. We think that a difference in promoter strength could explain the weaker immune response obtained in our study. However, the 85A antigen and the other members of the 85 complex are abundantly secreted into the mycobacterial culture supernatants of a variety of mycobacteria (50) and are able to induce an immune response in humans infected by M. tuberculosis (14) , implying that these proteins are produced in vivo in infected subjects. Experiments designed to compare the promoter strength of the 85A antigen promoter with that of other promoters are currently under way. We are currently also testing other model antigens that may provide information about the role of the nature of the antigen in achieving an efficient immune response in animals immunized with recombinant BCG using the 85A promoter and signal peptide.
